Year |
Citation |
Score |
2021 |
Huang SS, Lee KJ, Chen HC, Prajnamitra RP, Hsu CH, Jian CB, Yu XE, Chueh DY, Kuo CW, Chiang TC, Choong OK, Huang SC, Beh CY, Chen LL, Lai JJ, et al. Immune cell shuttle for precise delivery of nanotherapeutics for heart disease and cancer. Science Advances. 7. PMID 33893103 DOI: 10.1126/sciadv.abf2400 |
0.339 |
|
2018 |
Sung YC, Liu YC, Chao PH, Chang CC, Jin PR, Lin TT, Lin JA, Cheng HT, Wang J, Lai CP, Chen LH, Wu AY, Ho TL, Chiang T, Gao DY, et al. Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 8: 894-905. PMID 29463989 DOI: 10.7150/Thno.21168 |
0.501 |
|
2017 |
Chih-Chun C, Yang Y, Gao DY, Cheng HT, Hoang B, Chao PH, Chen LH, Bteich J, Chiang T, Liu JY, Li SD, Chen Y. Docetaxel-carboxymethylcellulose nanoparticles ameliorate CCl4-induced hepatic fibrosis in Mice. Journal of Drug Targeting. 1-27. PMID 29251522 DOI: 10.1080/1061186X.2017.1419358 |
0.743 |
|
2016 |
Liu CH, Chan KM, Chiang T, Liu JY, Chern GG, Hsu FF, Wu YH, Liu YC, Chen Y. Dual-functional nanoparticles targeting CXCR4 and delivering anti-angiogenic siRNA ameliorate liver fibrosis. Molecular Pharmaceutics. PMID 27224003 DOI: 10.1021/Acs.Molpharmaceut.5B00913 |
0.795 |
|
2015 |
Lin TT, Gao DY, Liu YC, Sung YC, Wan D, Liu JY, Chiang T, Wang L, Chen Y. Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. Journal of Controlled Release : Official Journal of the Controlled Release Society. PMID 26551344 DOI: 10.1016/J.Jconrel.2015.11.003 |
0.74 |
|
2015 |
Liu JY, Chiang T, Liu CH, Chern GG, Lin TT, Gao DY, Chen Y. Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26278330 DOI: 10.1038/Mt.2015.147 |
0.756 |
|
Show low-probability matches. |